TruBridge, Inc. (TBRG)
(Delayed Data from NSDQ)
$11.37 USD
+0.40 (3.65%)
Updated Jul 23, 2024 04:00 PM ET
After-Market: $11.35 -0.02 (-0.18%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Price, Consensus and EPS Surprise
TBRG 11.37 +0.40(3.65%)
Will TBRG be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TBRG based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TBRG
TruBridge (TBRG) Q1 Earnings Miss Estimates
TBRG: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for TBRG
TruBridge Achieves Consecutive Year HFMA Peer Reviewed Status for Complete Business Office and Revenue Cycle Management Solutions
TruBridge Announces Participation in the Stifel Cross Sector Insight Conference
TruBridge Awarded Peer Review Designation by Healthcare Financial Management Association
Analysts Offer Insights on Healthcare Companies: Acrivon Therapeutics, Inc. (ACRV), Arcutis Biotherapeutics (ARQT) and TruBridge (TBRG)
Analysts Have Conflicting Sentiments on These Healthcare Companies: Eli Lilly & Co (LLY), TruBridge (TBRG) and Ligand Pharma (LGND)